This suggests that targeting components like JAK2 or STAT proteins may help inhibit aberrant signaling and leukemic cell growth, thereby improving treatment outcomes for CML patients [33]. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.